Allergan has launched Juvéderm Volite, a hyaluronic-based injectable filler specifically designed to improve skin quality in the face, neck, décolletage and hands. Volite uses patented Vycross technology and is formulated to last up to nine months with a single treatment session. It should be injected intradermally and contains lidocaine for patient comfort.
In a clinical trial of 131 patients, Volite demonstrated an improvement in skin quality at one, four and six months. One month after treatment, 96% of patients’ cheeks were smoother (investigator assessment) and 91% of patients reported they were more satisfied with their skin. Results were sustained at six months, where patients reported that they continued to see significant improvements in skin hydration and were satisfied with their skin. Adverse events included bruising and pain at the injection site, however it was well tolerated overall and demonstrated an acceptable safety profile—95% of patients were able to return to social engagements one day after treatment. Final study results will be available in March 2017.
“The launch of Juvéderm Volite defines Allergan’s disruptive entrance into the skin quality category—an area that we know is set to experience huge growth over the next few years, and with a product designed to last up to nine months with just one treatment. As a market leader, this demonstrates our ongoing commitment to delivering medical aesthetic treatments that physicians and their patients really want, that is convenient for patients and doctors, and of high quality in its results and safety,” said Caroline Van Hove, senior vice president of international strategic marketing for medical aesthetics at Allergan.
